Stay up-to-date with the latest news in the medical aesthetics industry with our news roundup. This week's news includes a new leadership team at Sentient, Cutera's brand refresh, Elevai closing its initial public stock offering and Epionce opening a new distribution center in Houston, Texas.
Related: Obesity Treatment Updates: New FDA Approvals & Promising Clinical Trials
1. Sentient Adds to Leadership Team
Sentient has added to its executive leadership team: Brian Kirk joins as chief marketing officer and Jennifer Redmond joins as chief revenue officer.
Brian Kirk's new role includes elevating Sentient's marketing investment to support the continued success of Tixel by Sentient and Sentient Sculpt while advancing the Confidence Assured service, financing and warranty offerings. Jennifer Redmond will be responsible for leading all revenue growth functions for the company.
"We are excited to welcome Brian and Jen to our company," said Chris Cella, CEO and founder of Sentient. "In Sentient's first 14 years, we have diligently built our operations to offer industry-leading service and financial solutions, along with an exceptional suite of advanced proprietary technologies to practices of all sizes. With the addition of these two talented leaders, we are positioned to reach new heights, driving innovation, excellence and growth for aesthetics providers across America, and our support for consumers who want to look and feel their best with confidence assured."
Redmond, when asked about the latest trends in medical aesthetics, points towards an increased open-minded viewpoint from patients about treatment plans and continuous treatments compared to a single treatment approach.
"One evolution of aesthetics that I’ve noticed over my 18 years in the space is that patients are much more open to treatment plans and consider them part of their self-care regimen," Redmond said. "The practices that emphasize this with their patients do a great job of building plans that incorporate a combination of resurfacing and tightening, injectables and medical-grade skincare to help patients achieve their goals over time. In these plans, patients are seeking treatments and technologies that are less invasive, with minimal downtime and are open to coming in more frequently, versus a one-and-done, higher downtime approach."
2. Cutera Celebrates 25th Anniversary
Cutera celebrated its 25-year history and revealed a brand refresh, “A New Energy in Aesthetics,” at Cutera University Clinical Forum (CUCF) at The Encore, Las Vegas, its largest customer-facing event.
During the three-day event, Cutera showcased its latest innovations and best clinical practices, hosted interactive sessions and honored the success of customers nationwide. A panel of top industry experts shared their key insights, business learnings and challenging cases, empowering providers with results-driven clinical education. CUCF attendees received a first-hand look into the new Cutera brand while celebrating the company’s 25th anniversary and commitment to innovation.
“We wanted our CUCF attendees to experience how Cutera is bringing new energy to the aesthetics industry,” said Taylor Harris, CEO of Cutera, Inc. “The ‘New Energy’ concept is grounded in our roots of engineering excellence while highlighting the future of transformative patient outcomes through the power of technology, people and partnership. Our goal is nothing short of being the best company in aesthetics to work with and for.”
“We are thrilled to have been able to offer our customers an in-depth insight into our new advancements at this year’s Cutera University Clinical Forum” said Steve Kreider, senior vice president of global marketing Cutera, Inc. “With this event’s rich history, announcing our brand refresh is just the beginning as we usher in a new era of Cutera in 2024 and beyond.”
3. Elevai Labs Closes Common Stock Offering
Elevai announced the closing of its initial public offering of 1,500,000 shares of common stock at a public offering price of $4.00 per share for total gross proceeds of $6,000,000, before deducting underwriting discounts and other offering expenses.
Elevai intends to use the proceeds from the offering for business expansion and to broaden the sales reach, strengthen the market position and expand the scope of product offerings and working capital.
The shares of common stock began trading on the Nasdaq Capital Market on November 21, 2023, under the ticker symbol “ELAB.” The company has granted the underwriters an option, within 45 days from the closing date of the offering, to purchase up to an additional 225,000 shares of common stock at the public offering price, less underwriting discounts, to cover over-allotment, if any.
Univest and Webull were acting as co-underwriters for the offering. Ortoli Rosenstadt LLP was acting as U.S. counsel to the company and Hunter Taubman Fischer & Li LLC was acting as U.S. counsel to the underwriters in connection with the offering.
4. Epionce Opens New Distribution Center
Episciences, Inc., the exclusive manufacturer and distributor of Epionce, has announced the opening of a new distribution center outside of Houston, Texas. The new center will support Epionce's significant growth in the central and eastern regions of the United States.
The strategic decision to open a new Episciences, Inc. facility in the Houston metro area will more than double the current processing capacity and expedite faster shipping to customers, according to the company. Carl Thornfeldt, M.D., CEO of Episciences, Inc. and inventor of the Epionce skincare line., visited the new facility with his senior leadership team for an official walkthrough of the new space and meet and greet with the employees.
Related: Carl Thornfeldt, M.D., On Becoming the Father of Skin Barrier Repair
“We are excited to reveal this new strategic distribution center expansion which allows us to more than double our current processing capacity,” said Dr. Thornfeldt. “Over the last 20 years, the Epionce brand has grown from grassroots beginnings. Because we are based in Boise, Idaho, our efforts have been more focused on regions surrounding us. However, as the Epionce brand continues to grow its presence nationwide, changes were necessary to facilitate continuing to provide great customer service.”
Chad Thayer, chief operating officer of Episciences, Inc., said, “This facility will not only enable us to enhance our operational capabilities but also, due to its excellent location, will ensure timely and efficient delivery of our products to our valued customers in the central and eastern states. By freeing up capacity in our original Boise distribution center, our customers in the western states will also benefit from improved processing times. This is a true win for our customers everywhere. We are extremely grateful to all our employees and collaborators who worked tirelessly to bring this new facility to life in support of our expansion goals.”
